Zhao F, An R, Ma Y, Yu S, Gao Y, Wang Y
Clin Transl Med. 2025; 15(3):e70273.
PMID: 40070022
PMC: 11897063.
DOI: 10.1002/ctm2.70273.
Tsuchiya T, Miyawaki S, Teranishi Y, Ohara K, Hirano Y, Ogawa S
Acta Neuropathol Commun. 2025; 13(1):24.
PMID: 39910685
PMC: 11796276.
DOI: 10.1186/s40478-025-01937-w.
Keshri P, Singh S
Arch Toxicol. 2024; 98(10):3169-3190.
PMID: 39136731
DOI: 10.1007/s00204-024-03829-9.
Ma S, Xu Y, Qin X, Tao M, Gu X, Shen L
Cell Mol Biol Lett. 2024; 29(1):95.
PMID: 38956466
PMC: 11218243.
DOI: 10.1186/s11658-024-00610-9.
Mierke C
Cells. 2024; 13(1).
PMID: 38201302
PMC: 10777970.
DOI: 10.3390/cells13010096.
Navigating the ERK1/2 MAPK Cascade.
Martin-Vega A, Cobb M
Biomolecules. 2023; 13(10).
PMID: 37892237
PMC: 10605237.
DOI: 10.3390/biom13101555.
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
Belli S, Esposito D, Allotta A, Servetto A, Ciciola P, Pesapane A
NPJ Breast Cancer. 2023; 9(1):48.
PMID: 37258566
PMC: 10232479.
DOI: 10.1038/s41523-023-00556-9.
Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K/mTOR, and PAK1-regulated MAPK.
Nussinov R, Yavuz B, Arici M, Demirel H, Zhang M, Liu Y
Biophys Rev. 2023; 15(2):163-181.
PMID: 37124926
PMC: 10133437.
DOI: 10.1007/s12551-023-01054-9.
Development and Utility of a PAK1-Selective Degrader.
Chow H, Karchugina S, Groendyke B, Toenjes S, Hatcher J, Donovan K
J Med Chem. 2022; 65(23):15627-15641.
PMID: 36416208
PMC: 10029980.
DOI: 10.1021/acs.jmedchem.2c00756.
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas.
Zhu E, Riordan J, Vanneste M, Henry M, Stipp C, Dupuy A
NPJ Precis Oncol. 2022; 6(1):74.
PMID: 36271142
PMC: 9587254.
DOI: 10.1038/s41698-022-00310-7.
Germline mutations in could be associated with serrated polyposis syndrome.
Soares de Lima Y, Arnau-Collell C, Munoz J, Herrera-Pariente C, Moreira L, Ocana T
J Med Genet. 2022; 60(6):557-567.
PMID: 36270769
PMC: 10313964.
DOI: 10.1136/jmg-2022-108684.
ERK signaling for cell migration and invasion.
Samson S, Khan A, Mendoza M
Front Mol Biosci. 2022; 9:998475.
PMID: 36262472
PMC: 9573968.
DOI: 10.3389/fmolb.2022.998475.
The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC.
Wang D, Li Y, Ge H, Ghadban T, Reeh M, Gungor C
Cancers (Basel). 2022; 14(16).
PMID: 36010993
PMC: 9406497.
DOI: 10.3390/cancers14163998.
Tumor-matrix interaction induces phenotypic switching in liver cancer cells.
Yuan R, Hsu C, Jhuang Y, Liu Y, Hsieh T, Jeng Y
Hepatol Int. 2022; 16(3):562-576.
PMID: 35525880
DOI: 10.1007/s12072-022-10315-w.
Cell Signaling Pathways That Promote Radioresistance of Cancer Cells.
Ouellette M, Zhou S, Yan Y
Diagnostics (Basel). 2022; 12(3).
PMID: 35328212
PMC: 8947583.
DOI: 10.3390/diagnostics12030656.
Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects.
Zhang Y, Long J, Ren J, Huang X, Zhong P, Wang B
Front Oncol. 2021; 11:731441.
PMID: 34646772
PMC: 8503266.
DOI: 10.3389/fonc.2021.731441.
Long-Term Hypoxia Maintains a State of Dedifferentiation and Enhanced Stemness in Fetal Cardiovascular Progenitor Cells.
Knox C, Camberos V, Ceja L, Monteon A, Hughes L, Longo L
Int J Mol Sci. 2021; 22(17).
PMID: 34502291
PMC: 8431563.
DOI: 10.3390/ijms22179382.
The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction.
Soriano O, Alcon-Perez M, Vicente-Manzanares M, Castellano E
Genes (Basel). 2021; 12(6).
PMID: 34071831
PMC: 8229961.
DOI: 10.3390/genes12060819.
RSU-1 interaction with prohibitin-2 links cell-extracellular matrix detachment to downregulation of ERK signaling.
Wang M, Liu J, Tu Y, Zhao Z, Qu J, Chen K
J Biol Chem. 2021; 296:100109.
PMID: 33853759
PMC: 7948471.
DOI: 10.1074/jbc.RA120.014413.
PAK1 Positively Regulates Oligodendrocyte Morphology and Myelination.
Brown T, Hashimoto H, Finseth L, Wood T, Macklin W
J Neurosci. 2021; 41(9):1864-1877.
PMID: 33478987
PMC: 7939082.
DOI: 10.1523/JNEUROSCI.0229-20.2021.